全文获取类型
收费全文 | 365篇 |
免费 | 20篇 |
国内免费 | 12篇 |
专业分类
儿科学 | 40篇 |
妇产科学 | 3篇 |
基础医学 | 20篇 |
口腔科学 | 12篇 |
临床医学 | 40篇 |
内科学 | 81篇 |
皮肤病学 | 5篇 |
神经病学 | 11篇 |
特种医学 | 71篇 |
外科学 | 22篇 |
综合类 | 16篇 |
预防医学 | 19篇 |
药学 | 36篇 |
肿瘤学 | 21篇 |
出版年
2023年 | 2篇 |
2021年 | 1篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 9篇 |
2017年 | 9篇 |
2016年 | 2篇 |
2015年 | 7篇 |
2014年 | 11篇 |
2013年 | 19篇 |
2012年 | 13篇 |
2011年 | 4篇 |
2010年 | 21篇 |
2009年 | 17篇 |
2008年 | 5篇 |
2007年 | 7篇 |
2006年 | 13篇 |
2005年 | 9篇 |
2004年 | 6篇 |
2003年 | 12篇 |
2002年 | 2篇 |
2001年 | 5篇 |
2000年 | 8篇 |
1999年 | 14篇 |
1998年 | 29篇 |
1997年 | 19篇 |
1996年 | 21篇 |
1995年 | 17篇 |
1994年 | 16篇 |
1993年 | 13篇 |
1992年 | 5篇 |
1991年 | 2篇 |
1990年 | 6篇 |
1989年 | 8篇 |
1988年 | 5篇 |
1987年 | 7篇 |
1986年 | 9篇 |
1985年 | 5篇 |
1984年 | 4篇 |
1983年 | 4篇 |
1982年 | 3篇 |
1981年 | 4篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 2篇 |
1973年 | 1篇 |
1950年 | 1篇 |
排序方式: 共有397条查询结果,搜索用时 0 毫秒
31.
克泻灵片中苦参碱类生物碱的HPLC分析 总被引:8,自引:0,他引:8
目的:对克泻灵片中主要有效生物碱定性、定量。完善产品的质量控制及评价手段。方法:采用HPLC,紫外测定波长:220nm。结果:片剂中有有效生物碱以苦参碱类生物碱为主,其中苦参碱和槐定碱含量高,分别占总生物碱的14.2%~31.6%和22.6%~62.7%,其次为槐颗碱和槐胺碱,氧化苦参碱的含量很低。结论:建立了HPLC测定克泻灵片中主要生物碱,方法简便快捷,精密度好,回收率高,可用于制剂及原料的质量控制。 相似文献
32.
Complementary medicine: use and attitudes among GPs 总被引:9,自引:0,他引:9
BACKGROUND: Information about use and attitudes of GPs towards
complementary medicine is required in order to inform the debate about its
place within mainstream medicine. There is evidence that public use of
complementary medicine is particularly high in the South-West of England.
OBJECTIVE: This study aimed to determine the use of, and attitudes towards,
complementary medicine among GPs. METHODS: A questionnaire survey was
performed of all primary care physicians working in the health service in
Devon and Cornwall. RESULTS: Replies were received from 461 GPs, a response
rate of 47%. A total of 314 GPs (68%, range 32-85%) had been involved in
complementary medicine in some way during the previous week. One or other
form of complementary medicine was practised by 74 of the respondents
(16%), the two most common being homoeopathy (5.9%) and acupuncture (4.3%).
In addition, 115 of the respondents (25%) had referred at least one patient
to a complementary therapist in the previous week, and 253 (55%) had
endorsed or recommended treatment with complementary medicine.
Chiropractic, acupuncture and osteopathy were rated as the three most
effective therapies, and the majority of respondents believed that these
three therapies should be funded by the health service. A total of 176
(38%) of respondents reported adverse effects, most commonly after
manipulation. CONCLUSION: Over two-thirds of the GPs in Devon and Cornwall
who responded to the survey had been involved with complementary medicine
in some way during the previous week. This figure is higher than the
national average. The majority of respondents believed that acupuncture,
chiropractic and osteopathy were effective and should be funded by the NHS.
相似文献
33.
BC SHARMA RP SINGH YK CHAWLA KL NARASIMHAN KLN RAO SK MITRA JB DILAWARI 《Journal of gastroenterology and hepatology》1997,12(8):582-584
Shunt surgery is considered to be the treatment of choice in patients with non-cirrhotic portal hypertension. There is little data on the effect of side-to-side lieno-renal (SSLR) shunt on oesophageal variceal size, splenic size and splenic pulp pressure (SPP) in patients with non-cirrhotic portal hypertension. We evaluated pre- and postoperatively endoscopic grading of varices, splenic size and SPP for predicting shunt patency in 86 patients with non-cirrhotic portal hypertension: 56 with extrahepatic portal venous obstruction (EHPVO) and 30 with non-cirrhotic portal fibrosis (NCPF). The EHPVO patients with patent shunts (n= 47) showed significant reduction in SPP (pre-operative 43.56±7.9 vs postoperative 29.96±7.7 cm of saline), splenic size (6.5±2.8 vs 4.00±2.6 cm below costal margin) and varices grades (2.96±0.5 vs 0.92±0.8). Patients with blocked shunt (n= 9) did not show significant reduction in SPP and varices grades. However, there was reduction in spleen size (8.6±3.0 vs 6.3±4.3). In the NCPF group, 28 had patent shunts and showed significant reduction in SPP (46.3±13.5 vs 33.8±7.6 cm of saline), splenic size (9.1±3.3 vs 6.8±4.6 cm below costal margin) and varices grades (2.8±0.7 vs 1.05±0.96). As only two patients with NCPF had blocked shunts, no statistical comparison between patients with patent and patients with blocked shunts could be done. In conclusion, following SSLR, there is a significant reduction in SPP and varices grades in patients with patent shunts. Endoscopic grading of varices can be used to predict shunt patency. However, spleen size is not a good criteria for predicting shunt patency. 相似文献
34.
35.
36.
37.
38.
Francis KL CHAN 《Journal of digestive diseases》2005,6(1):1-5
Whether Helicobacter pylori infection alters the risk of ulcer disease in patients receiving nonsteroidal anti‐inflammatory drugs (NSAIDs) or low‐dose aspirin is one of the most controversial topics in peptic ulcer research. This is an important management issue, particularly in countries where peptic ulcer disease is common and the prevalence of H. pylori infection is high. Current evidence shows that H. pylori infection increases the ulcer risk associated with NSAIDs or low‐dose aspirin. Eradication of H. pylori reduces the subsequent risk of endoscopic and complicated ulcers in patients who are about to start long‐term NSAIDs. Among patients with H. pylori infection and a history of ulcer bleeding who continue to use low‐dose aspirin, 1 week of eradication therapy prevents recurrent ulcer bleeding. Failure of eradication and concomitant use of NSAIDs, however, account for most cases of recurrent bleeding with low‐dose aspirin. The apparent protective effect of H. pylori in long‐term NSAIDs users reported in some studies was actually the weeding out of susceptible patients who were intolerant to NSAIDs. There is no convincing evidence that eradication of H. pylori has any clinically important adverse effect on the healing and prevention of ulcers in NSAIDs users. 相似文献
39.
世界胃肠病学组织(WGO-OMGE)临床指南——发展中国家幽门螺杆菌感染 总被引:16,自引:1,他引:16
Hunt RH Xiao SD Megraud F Leon-Barua R Bazzoli F Van der Merwe S vaz Coelho LG Fock KM Fedail S Cohen H Malfertheiner P Vakil N Hamid S Goh KL Wong BC Krabshuis JH 杜颖 丛衍群 戴宁 《胃肠病学》2007,12(1):40-52
我非常高兴向大家推荐这份发展中国家幽门螺杆菌(H.priori)临床指南。该指南的编译是由数位在该领域具有丰富临床经验的世界知名专家共同完成的。 相似文献
40.